retatrutide type 2 diabetes phase 2 results 2024 2025 Lilly's triple agonist delivers up to 71.2 lbs of weight loss Phase III retatrutide study demonstrates

Several factors likely contributed to this heterogeneity

Current FDA-approved prescribing information for semaglutide does not require routine thyroid monitoring, including serum calcitonin measurements or thyroid ultrasound surveillance, in patients without risk factors

Many patients benefit from structured accountabilitywhether through food logging apps, dietitian check-ins, or community supportduring the transition off GLP-1

if hair removal is necessary, patients should use scissors to trim rather than shaving, which can cause micro-abrasions

For the scenario of "Currently Available Treatment," research data suggests Tirzepatide may be more relevant

Koch KL, Hasler WL, Yates KP, et al